SCHEMBL4077923

SCHEMBL4077923

CC(C)CN1CCC2(CC1)CCN(CCCn1ccnc1CN(C)Cc1nc3ccccc3[nH]1)C2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 4/20 0.39
TDP1 Q9NUW8 1/20 0.36
BACE1 P56817 1/20 0.36
DRD4 P21917 7/20 0.36
CYP3A4 P08684 2/20 0.36
DRD2 P14416 3/20 0.35
DRD3 P35462 2/20 0.35
HTR1A P08908 1/20 0.35
HTR7 P34969 1/20 0.35
HRH1 P35367 1/20 0.35
BCHE P06276 1/20 0.35
OPRM1 P35372 1/20 0.34
OPRL1 P41146 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
ALOX15 P16050 1/20 0.34
OPRK1 P41145 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
LMNA P02545 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4068595 0.89 TDP1 (0.35) CXCR4TDP1DRD4CYP3A4DRD2
SCHEMBL4067101 0.86 TDP1 (0.41) CXCR4TDP1CYP3A4OPRM1OPRL1
SCHEMBL4067003 0.85 OPRM1 (0.43) CXCR4CYP3A4OPRM1OPRL1ALDH1A1
SCHEMBL4067735 0.85 CXCR4 (0.52) CXCR4CYP3A4HRH1OPRM1OPRL1
SCHEMBL4069468 0.83 CXCR4 (0.52) CXCR4CYP3A4HRH1OPRM1OPRL1
SCHEMBL4073134 0.82 CXCR4 (0.40) CXCR4CYP3A4OPRM1OPRL1ALDH1A1
SCHEMBL4069969 0.80 CXCR4 (0.37) CXCR4CYP3A4OPRM1OPRL1ALDH1A1
SCHEMBL4070793 0.80 CXCR4 (0.54) CXCR4CYP3A4ALDH1A1ALOX15TSHR
SCHEMBL4067508 0.79 CXCR4 (0.41) CXCR4CYP3A4ALDH1A1ALOX15TSHR
SCHEMBL4065760 0.79 CXCR4 (0.41) CXCR4CYP3A4ALDH1A1ALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325992-A1 COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2055705-A1 COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF Ono Pharmaceutical CO., LTD. (JP) 2009-05-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325992-A1 COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF CXCR4, CXCL12, CXCR1 CXCR4 1/4885TDP1 3896/4885BACE1 2696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.